Envestnet Asset Management
BMY.RT

Envestnet Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Envestnet Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,256
Closed -$51K – 3232
2020
Q2 		$51K Buy
+14,256
New +$51.4K ﹤0.01% 3024
2020
Q1 		– Sell
-23,727
Closed -$71K – 3202
2019
Q4 		$71K Buy
+23,727
New +$61.7K ﹤0.01% 3028

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Envestnet Asset Management's BMY.RT Position: Q3 2020 in Review

Envestnet Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 14,256 shares — an estimated $51K sold.

Envestnet Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 2 quarters. The position peaked at $71K in Q4 2019. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Envestnet Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Envestnet Asset Management sold 14,256 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $51K.
  • Envestnet Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 2 quarters.
  • Envestnet Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $71K in Q4 2019.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Envestnet Asset Management's 13F filing for Q3 2020, filed 9 Oct 2020.